Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection

Background To investigate the association between serum 25-hydroxyvitamin D levels and its effect on adverse clinical outcomes, and parameters of immune function and mortality due to a SARS-CoV-2 infection. Study design The hospital data of 235 patients infected with COVID-19 were analyzed. Results Based on CDC criteria, among our study patients, 74% had severe COVID-19 infection and 32.8% were vitamin D sufficient. After adjusting for confounding factors, there was a significant association between vitamin D sufficiency and reduction in clinical severity, inpatient mortality serum levels of C-reactive protein (CRP) and an increase in lymphocyte percentage. Only 9.7% of patients older than 40 years who were vitamin D sufficient succumbed to the infection compared to 20% who had a circulating level of 25(OH)D< 30 ng/ml. The significant reduction in serum CRP, an inflammatory marker, along with increased lymphocytes percentage suggest that vitamin D sufficiency also may help modulate the immune response possibly by reducing risk for cytokine storm in response to this viral infection. Conclusion Therefore, it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.

[1]  Yuan-Chuan Chen,et al.  Novel Antiviral Strategies in the Treatment of COVID-19: A Review , 2020, Microorganisms.

[2]  A. Peleg,et al.  Remdesivir for the Treatment of Covid-19 - Preliminary Report. , 2020, The New England journal of medicine.

[3]  Lee-Jen Wei,et al.  Remdesivir for the Treatment of Covid-19 - Preliminary Report. , 2020, The New England journal of medicine.

[4]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[5]  Patrick W. Johnson,et al.  Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. , 2020, The Journal of clinical investigation.

[6]  S. Perera,et al.  Early changes in bone turnover predict longer-term changes in bone mineral density but not trabecular bone score in frail older women , 2020, Archives of Osteoporosis.

[7]  R. Petriș,et al.  Seasonal periodicity of serum parathyroid hormone and its relation with vitamin D in Romania , 2020, Archives of Osteoporosis.

[8]  Hans Clevers,et al.  SARS-CoV-2 productively infects human gut enterocytes , 2020, Science.

[9]  R. Xiang,et al.  WIP1 promotes cancer stem cell properties by inhibiting p38 MAPK in NSCLC , 2020, Signal Transduction and Targeted Therapy.

[10]  Chaochao Tan,et al.  C‐reactive protein correlates with computed tomographic findings and predicts severe COVID‐19 early , 2020, Journal of medical virology.

[11]  V. Backman,et al.  The Possible Role of Vitamin D in Suppressing Cytokine Storm and Associated Mortality in COVID-19 Patients , 2020 .

[12]  Lee Smith,et al.  The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality , 2020, Aging Clinical and Experimental Research.

[13]  Quynh Nguyen,et al.  Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System , 2020, Circulation research.

[14]  Cdc Covid- Response Team.  Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020 , 2020 .

[15]  Emily N. Ussery,et al.  Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[16]  L. Wang,et al.  C-reactive protein levels in the early stage of COVID-19 , 2020, Médecine et Maladies Infectieuses.

[17]  Hongming Miao,et al.  Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study , 2020, Signal Transduction and Targeted Therapy.

[18]  H. Ashraf,et al.  Rationale and Design of a Registry in a Referral and Educational Medical Center in Tehran, Iran: Sina Hospital Covid-19 Registry (SHCo-19R) , 2020 .

[19]  D. Cucinotta,et al.  WHO Declares COVID-19 a Pandemic , 2020, Acta bio-medica : Atenei Parmensis.

[20]  M. L. Serrano,et al.  Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis , 2020, EXCLI journal.

[21]  Kai Liu,et al.  Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients , 2020, Journal of Infection.

[22]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[23]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[24]  M. Holick,et al.  Disassociation of Vitamin D’s Calcemic Activity and Non-calcemic Genomic Activity and Individual Responsiveness: A Randomized Controlled Double-Blind Clinical Trial , 2019, Scientific Reports.

[25]  William S. Hlavacek,et al.  Prediction of Optimal Drug Schedules for Controlling Autophagy , 2018, Scientific Reports.

[26]  Beata M. Gruber-Bzura.  Vitamin D and Influenza—Prevention or Therapy? , 2018, International journal of molecular sciences.

[27]  M. Moosazadeh,et al.  High Prevalence of Vitamin D Deficiency among Iranian Population: A Systematic Review and Meta-Analysis , 2018, Iranian journal of medical sciences.

[28]  Q. Luo,et al.  Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system , 2017, Molecular medicine reports.

[29]  David A. Jolliffe,et al.  Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data , 2017, British Medical Journal.

[30]  B. Larijani,et al.  Vitamin D deficiency, bone turnover markers and causative factors among adolescents: a cross-sectional study , 2016, Journal of Diabetes & Metabolic Disorders.

[31]  D. Bikle.  Extraskeletal actions of vitamin D , 2016, Annals of the New York Academy of Sciences.

[32]  Min‐ge Xie,et al.  Temporal Relationship between Vitamin D Status and Parathyroid Hormone in the United States , 2015, PloS one.

[33]  M. Holick,et al.  Vitamin D for health: a global perspective. , 2013, Mayo Clinic proceedings.

[34]  E. Hyppönen,et al.  Vitamin D status has a linear association with seasonal infections and lung function in British adults , 2011, British Journal of Nutrition.

[35]  C. Gordon,et al.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[36]  R. Striker,et al.  Vitamin D and the anti-viral state. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[37]  JoAnn E. Manson,et al.  The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know , 2010, The Journal of clinical endocrinology and metabolism.

[38]  D. Bruce,et al.  Vitamin D and host resistance to infection? Putting the cart in front of the horse , 2010, Experimental biology and medicine.

[39]  S. Boonen,et al.  IOF position statement: vitamin D recommendations for older adults , 2010, Osteoporosis International.

[40]  R. Langan,et al.  Recognition and management of vitamin D deficiency. , 2009, American family physician.

[41]  K. Shiozawa,et al.  1 alpha,25-dihydroxyvitamin D3 inhibits pokeweed mitogen-stimulated human B-cell activation: an analysis using serum-free culture conditions. , 1985, Immunology.

[42]  R E Hope-Simpson,et al.  The role of season in the epidemiology of influenza , 1981, Journal of Hygiene.